Anales RANF

Nannocannabinoids for brain tumor drug delivery @Real Academia Nacional de Farmacia. Spain 211 the particle size of LNCs. This fine size-tailoring can be achieved by the PIT method thanks to the herein-described linear univariate mathematical model as a function of the oily phase/surfactant mass ratio to increase the chances of success in the development of nanomedicines for the treatment of glioma and other brain diseases. Consequently, they deserve subsequent in vivo evaluation in an animal model of disease. Acknowledgements This work was supported by the Complutense Research Fund (Ref. 16/83) and by the Santander-UCM Research Group GR35/10: Parenteral Administration of Drugs. J. A.-B. would like to thank the Spanish Ministry of Education for his contract within the Professor Training Program FPU (Ref. FPU13/02325) and for funding two research stays at the School of Life, Health and Chemical Sciences, The Open University (Refs. EST15/00534 and EST16/00556) and a research stay at L'unité Micro et Nanomédecines Biomimétiques (MINT) INSERM 1066 CNRS 6021, Université d’Angers (Ref. EST14/00229). Conflict of interest The authors declare no competing interests 5. REFERENCES 1. Silberberg D, Anand NP, Michels K, Kalaria RN. Brain and other nervous system disorders across the lifespan - global challenges and opportunities. Nature. 2015;527:S151-S4. 2. Oberoi RK, Parrish KE, Sio TT, Mittapalli RK, Elmquist WF, Sarkaria JN. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma. Neuro-Oncology. 2016;18:27-36. 3. Tsou YH, Zhang XQ, Zhu H, Syed S, Xu XY. Drug Delivery to the Brain across the Blood-Brain Barrier Using Nanomaterials. Small. 2017;13:1701921. 4. Zhou YQ, Peng ZL, Seven ES, Leblanc RM. Crossing the blood-brain barrier with nanoparticles. Journal of Controlled Release. 2018;270:290-303. 5. Kaushik A, Jayant RD, Bhardwaj V, Nair M. Personalized nanomedicine for CNS diseases. Drug discovery today. 2018;23:1007-15. 6. Liebner S, Dijkhuizen RM, Reiss Y, Plate KH, Agalliu D, Constantin G. Functional morphology of the blood-brain barrier in health and disease. Acta Neuropathologica. 2018;135:311-36. 7. Roger K. Nanoemulsification in the vicinity of phase inversion: Disruption of bicontinuous structures in oil/surfactant/water systems. Current Opinion in Colloid & Interface Science. 2016;25:120-8. 8. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica. 2016;131:803-20. 9. Alifieris C, Trafalis DT. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacology & Therapeutics. 2015;152:63-82. 10. Velasco G, Hernandez-Tiedra S, Davila D, Lorente M. The use of cannabinoids as anticancer agents. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2016;64:259-66. 11. Fowler CJ. Delta(9)-Tetrahydrocannabinol and Cannabidiol as Potential Curative Agents for Cancer: A Critical Examination of the Preclinical Literature. Clinical Pharmacology & Therapeutics. 2015;97:587- 96. 12. Andre CM, Hausman JF, Guerriero G. Cannabis sativa: The Plant of the Thousand and One Molecules. Frontiers in Plant Science. 2016;7:19. 13. Russo EB. Beyond Cannabis: Plants and the Endocannabinoid System. Trends in Pharmacological Sciences. 2016;37:594-605. 14. Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, et al. Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther. 2017;175:133-50. 15. Xie JR, Xiao DJ, Zhao JN, Hu NQ, Bao Q, Jiang L, et al. Mesoporous Silica Particles as a Multifunctional Delivery System for Pain Relief in Experimental Neuropathy. Advanced Healthcare Materials. 2016;5:1213-21. 16. Martin-Banderas L, Munoz-Rubio I, Prados J, Alvarez-Fuentes J, Calderon-Montano JM, Lopez- Lazaro M, et al. In vitro and in vivo evaluation of Delta(9)-tetrahidrocannabinol/PLGA nanoparticles for cancer chemotherapy. International Journal of Pharmaceutics. 2015;487:205-12. 17. Martin-Banderas L, Munoz-Rubio I, Alvarez-Fuentes J, Duran-Lobato M, Arias JL, Holgado MA, et al. Engineering of Delta(9)-tetrahydrocannabinol delivery systems based on surface modified-PLGA nanoplatforms. Colloids and Surfaces B-Biointerfaces. 2014;123:114-22. 18. Cherniakov I, Izgelov D, Barasch D, Davidson E, Domb AJ, Hoffman A. Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration. Journal of Controlled Release. 2017;266:1-7. 19. Ligresti A, De Petrocellis L, de la Ossa DHP, Aberturas R, Cristino L, Moriello AS, et al. Exploiting Nanotechnologies and TRPV1 Channels to Investigate the Putative Anandamide Membrane Transporter. Plos One. 2010;5:12. 20. Esposito E, Ravani L, Drechsler M, Mariani P, Contado C, Ruokolainen J, et al. Cannabinoid antagonist in nanostructured lipid carriers (NLCs): design, characterization and in vivo study. Materials Science & Engineering C-Materials for Biological Applications. 2015;48:328-36.